Tislelizumab,Sorafenib
BeiGene,bayer
['tislelizumab', 'beigene', '$bgne']
beigene announces data presentations at esmo 2022 including late-breaking oral presentation for tislelizumab in first-line unresectable hepatocellular cancer $bgne 
Run by investors, for investors.

Real-time:
PRs
Gov. contract awards
Earnings
M&As
FDA approvals
Insider trades
SEC filings
And more

Not investment advice